Abstract
Metabolomics, one of the latest omics’ technologies, focuses on the global, quantitative, and simultaneous measurement of endogenous metabolites in a biological sample. Investigation of either individual metabolites, a panel of metabolites, or a broad metabolite profile (metabolome) can be carried out in cells, tissues, or body fluids. Recent publications indicate that there is an enormous, constantly growing multitude of metabolomics applications in oncology. As a translational research tool, metabolomics provides a link between basic in vitro laboratory data to in vivo preclinical results and clinical oncology and enables systems biology insights. In the present chapter, the current and potential future applications of metabolomics in PDAC research are focused on the clinical aspects of diagnostics.
Peter McGranaghan and Ulrike Rennefahrt contributed equally to this manuscript.
Similar content being viewed by others
References
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–83.
Fiehn O. Metabolomics – the link between genotypes and phenotypes. Plant Mol Biol. 2002;48(1–2):155–71.
Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431–40.
Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26(1):51–78.
Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol. 2004;5(9):763–9.
van der Greef J, Smilde AK. Symbiosis of chemometrics and metabolomics: past, present, and future. J Chemom. 2005;19(5–7):376–86.
Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054–6.
Bothwell JH, Griffin JL. An introduction to biological nuclear magnetic resonance spectroscopy. Biol Rev. 2011;86(2):493–510.
Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol. 2003;7(5):648–54.
Defernez M, Colquhoun IJ. Factors affecting the robustness of metabolite fingerprinting using 1 H NMR spectra. Phytochemistry. 2003;62(6):1009–17.
Büscher JM, Czernik D, Ewald JC, Sauer U, Zamboni N. Cross-platform comparison of methods for quantitative metabolomics of primary metabolism. Anal Chem. 2009;81(6):2135–43.
Bennett BD, Yuan J, Kimball EH, Rabinowitz JD. Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. Nat Protoc. 2008;3(8):1299–311.
Perera RM, Bardeesy N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 2015;5(12):1247–61.
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Prim. 2015;2:16022.
Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656–70.
Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060–83.
Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E, Nicholson JK. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2013;8(1):17–32.
Kamlage B, Maldonado SG, Bethan B, Peter E, Schmitz O, Liebenberg V, Schatz P. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin Chem. 2014;60(2):399–412.
Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci. 2015;112(32):E4410–7.
Fujimura Y, Ikenaga N, Ohuchida K, Setoyama D, Irie M, Miura D, Wariishi H, Murata M, Mizumoto K, Hashizume M, Tanaka M. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. Pancreas. 2014;43(2):311–8.
Grüner BM, Winkelmann I, Feuchtinger A, Sun N, Balluff B, Teichmann N, Herner A, Kalideris E, Steiger K, Braren R, Aichler M, et al. Modeling therapy response and spatial tissue distribution of erlotinib in pancreatic cancer. Mol Cancer Ther. 2016;15(5):1145–52.
Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296–300.
Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, Mukohara T, Nishiumi S, Azuma T, Yoshida M, Minami H. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One. 2014;9(11):e113259.
Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193–8.
Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom. 2010;24(5):613–20.
**e G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, et al. Plasma metabolite biomarkers for the detection of pancreatic cancer. J Proteome Res. 2015;14(2):1195–202.
Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20(3):415–23.
Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22(4):571–9.
Sakai A, Suzuki M, Kobayashi T, Nishiumi S, Yamanaka K, Hirata Y, Nakagawa T, Azuma T, Yoshida M. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Biomark Med. 2016;10(6):577–86.
Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518–28.
Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, Pazienza V. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7(5):5815–29.
Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, map**, and evolution. J Proteome Res. 2012;11(2):1274–83.
Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2017 Jan 20. pii: gutjnl-2016-312432. doi: 10.1136/gutjnl-2016-312432.
Leichtle AB, Ceglarek U, Weinert P, Nakas CT, Nuoffer J-M, Kase J, et al. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics. 2013;9(3):677–87.
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78–95.
Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013;19(18):4983–93.
Fontana A, Copetti M, Di Gangi IM, Mazza T, Tavano F, Gioffreda D, Mattivi F, Andriulli A, Vrhovsek U, Pazienza V. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Oncotarget. 2016;7(8):8968–78.
Raftery MD, Asiago VM, Owusu-sarfo K, ** B, Inventors, Purdue Research Foundation, Assignee. Identification of blood based metabolite biomarkers of pancreatic cancer. United States patent application US 14/465,535. 2015 Feb 26.
Pastural E, Ritchie S, Inventors, Phenomenome Discoveries Inc., Assignee. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis. United States patent application US 13/499,369. 2010 Oct 1.
Reszka R, Kamlage B, Kalthoff H, Schniewind B, Mayerle J, Lerch MM, Pilarsky C, Grützmann R, Inventors, Metanomics Health GmbH, Assignee. Means and methods for diagnosing pancreatic cancer in a subject. United States patent application US 14/361,460. 2012 Nov 29.
Park WG, Pasricha PJ, Peltz G, Lowe A, Inventors, The Board of Trustees of the Leland Stanford Junior University, Assignee. Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts. United States patent application US 14/180,892. 2014 Aug21.
Fernández-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427–34.
Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423–33.
Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58(4):331–45.
Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, De Andrade M, Petersen GM. Pancreatic cancer–associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101.
Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014;20(9):2279–303.
Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, Pinault M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci. 2015;112(8):2473–8.
Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, ** W, Mochizuki A, Goodenowe DB. Pancreatic cancer serum biomarker PC-594: diagnostic performance and comparison to CA19-9. World J. Gastroenterol: WJG. 2015;21(21):6604–12.
Kamlage B, Reszka R, Peter E, Kastler J, Schatz P, Kalthoff H, Schniewind B, Mayerle J, Lerch M, Pilarsky C, Grützmann R, Inventors, Metanomics Health GmbH, Assignee. Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel. WO/2015/091962. 2015 June 25.
Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today. 2006;11(23):1085–92.
Wheelock CE, Wheelock ÅM, Kawashima S, Diez D, Kanehisa M, van Erk M, et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol BioSyst. 2009;5(6):588–602.
Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):165–76.
Balog J, Sasi-Szabó L, Kinross J, Lewis MR, Muirhead LJ, Veselkov K, Mirnezami R, Dezső B, Damjanovich L, Darzi A, Nicholson JK. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med. 2013;5(194):194ra93.
Droste P, Weitzel M, Wiechert W. Visual exploration of isotope labeling networks in 3D. Bioprocess Biosyst Eng. 2008;31(3):227–39.
Sauer U. Metabolic networks in motion: 13C-based flux analysis. Mol Syst Biol. 2006;2:62.
Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics. 2006;6(17):4716–23.
Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007;4(10):828–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media LLC
About this entry
Cite this entry
McGranaghan, P. et al. (2016). Approaching Pancreatic Cancer Phenotypes via Metabolomics. In: Neoptolemos, J., Urrutia, R., Abbruzzese, J., Büchler, M. (eds) Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6631-8_61-1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6631-8_61-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-6631-8
Online ISBN: 978-1-4939-6631-8
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences